Genexine, Inc. (095700.KQ)

KRW 5590.0

(-3.79%)

Revenue Summary of Genexine, Inc.

Genexine, Inc.'s latest annual revenue in 2023 was 4.42 Billion KRW , down -72.57% from previous year.
Genexine, Inc.'s latest quarterly revenue in 2024 Q2 was 344.49 Million KRW , down -83.38% from previous quarter.
Genexine, Inc. reported a annual revenue of 16.13 Billion KRW in annual revenue 2022, down -56.18% from previous year.
Genexine, Inc. reported a annual revenue of 36.82 Billion KRW in annual revenue 2021, up 98.61% from previous year.
Genexine, Inc. reported a quarterly revenue of 2.07 Billion KRW for 2024 Q1, up 35.1% from previous quarter.
Genexine, Inc. reported a quarterly revenue of 1.83 Billion KRW for 2023 Q2, up 164.71% from previous quarter.

Annual Revenue Chart of Genexine, Inc. (2023 - 2012)

Historical Annual Revenue of Genexine, Inc. (2023 - 2012)

Year	Revenue	Revenue Growth
2023	4.42 Billion KRW	-72.57%
2022	16.13 Billion KRW	-56.18%
2021	36.82 Billion KRW	98.61%
2020	18.54 Billion KRW	64.06%
2019	11.3 Billion KRW	-12.25%
2018	12.88 Billion KRW	-54.73%
2017	28.45 Billion KRW	150.66%
2016	11.35 Billion KRW	-65.09%
2015	32.51 Billion KRW	0.0%
2012	6.25 Billion KRW	0.0%

Year	Revenue	Revenue Growth
2024 Q2	344.49 Million KRW	-83.38%
2024 Q1	2.07 Billion KRW	35.1%
2023 Q2	1.83 Billion KRW	164.71%
2023 FY	4.42 Billion KRW	-72.57%
2023 Q4	1.53 Billion KRW	316.43%
2023 Q3	368.51 Million KRW	-79.88%
2023 Q1	691.91 Million KRW	-70.02%
2022 Q4	2.3 Billion KRW	-3.52%
2022 FY	16.13 Billion KRW	-56.18%
2022 Q1	10.81 Billion KRW	447.06%
2022 Q3	2.39 Billion KRW	282.11%
2022 Q2	626.1 Million KRW	-94.21%
2021 Q1	32.96 Billion KRW	289.69%
2021 FY	36.82 Billion KRW	98.61%
2021 Q2	1.64 Billion KRW	-95.02%
2021 Q3	247.2 Million KRW	-84.94%
2021 Q4	1.97 Billion KRW	699.51%
2020 Q3	681.85 Million KRW	-59.88%
2020 FY	18.54 Billion KRW	64.06%
2020 Q2	1.69 Billion KRW	-77.93%
2020 Q4	8.45 Billion KRW	1140.53%
2020 Q1	7.7 Billion KRW	110.07%
2019 Q2	2.77 Billion KRW	287.67%
2019 FY	11.3 Billion KRW	-12.25%
2019 Q4	3.66 Billion KRW	-11.5%
2019 Q3	4.14 Billion KRW	49.25%
2019 Q1	716.13 Million KRW	0.0%
2018 FY	12.88 Billion KRW	-54.73%
2017 FY	28.45 Billion KRW	150.66%
2016 FY	11.35 Billion KRW	-65.09%
2015 FY	32.51 Billion KRW	0.0%
2013 Q3	1.58 Billion KRW	0.0%
2012 Q3	811.38 Million KRW	0.0%
2012 FY	6.25 Billion KRW	0.0%

Peer Revenue Comparison of Genexine, Inc.

Name	Revenue	Revenue Difference
HLB Co., Ltd.	42.9 Billion KRW	89.682%
iNtRON Biotechnology, Inc.	9.58 Billion KRW	53.819%
BINEX Co., Ltd.	154.82 Billion KRW	97.141%
Bioneer Corporation	263.23 Billion KRW	98.318%
Anterogen.Co.,Ltd.	6.5 Billion KRW	31.901%
MEDIPOST Co., Ltd.	68.64 Billion KRW	93.551%
CrystalGenomics, Inc.	4.87 Billion KRW	9.266%
Helixmith Co., Ltd	4.2 Billion KRW	-5.355%
Chabiotech Co.,Ltd.	953.95 Billion KRW	99.536%
Medy-Tox Inc.	221.12 Billion KRW	97.998%
Peptron, Inc.	3.34 Billion KRW	-32.459%
Amicogen, Inc.	159.9 Billion KRW	97.232%
HLB Therapeutics Co.,Ltd.	53.74 Billion KRW	91.764%
LegoChem Biosciences, Inc.	34.14 Billion KRW	87.036%
ALTEOGEN Inc.	96.52 Billion KRW	95.414%
PharmaResearch Co., Ltd.	261.01 Billion KRW	98.304%
SillaJen, Inc.	3.93 Billion KRW	-12.364%
JETEMA, Co., Ltd.	58.71 Billion KRW	92.461%
OliX Pharmaceuticals,Inc	17.06 Billion KRW	74.059%
Genomictree Inc.	3.41 Billion KRW	-29.509%
MedPacto, Inc.	- KRW	-Infinity%
D&D Pharmatech	18.67 Billion KRW	76.299%
EASY BIO,Inc.	165.38 Billion KRW	97.323%
GI Innovation, Inc.	5.31 Billion KRW	16.775%